Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.

Gane, Edward J

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. [electronic resource] - Lancet (London, England) Oct 2010 - 1467-75 p. digital

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1474-547X

10.1016/S0140-6736(10)61384-0 doi


Administration, Oral
Adult
Antiviral Agents--administration & dosage
Cyclopropanes
Deoxycytidine--administration & dosage
Double-Blind Method
Drug Therapy, Combination
Female
Hepacivirus--genetics
Hepatitis C, Chronic--drug therapy
Humans
Interferon alpha-2
Interferon-alpha--administration & dosage
Isoindoles
Lactams--administration & dosage
Lactams, Macrocyclic
Male
Middle Aged
Polyethylene Glycols--administration & dosage
Proline--analogs & derivatives
RNA, Viral--blood
Recombinant Proteins
Sulfonamides--administration & dosage
Viral Nonstructural Proteins--antagonists & inhibitors